Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

NCT03499873 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

448

Enrollment

INDUSTRY

Sponsor class

Conditions

Cataract

Interventions

DRUG: Nepafenac 0.3% Oph Susp
DRUG: Placebos
DRUG: Nepafenac 0.3% Oph Susp (reference)

Sponsor

Actavis Inc.